Registered outcomes21

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 20 of 21

List	Outcome	Time frame	Description
Primary	Concentration of Zoledronic acid	Predose, 30 minutes, 2 hours, 24 hours, day 7, day 29, 3 months, 6 months, 12 months, 24 months, and 36 months post dose	Zoledronic acid concentration in plasma and urine.
Primary	Maximum concentration of Zoledronic acid	0-36 months	The observed maximum concentration following administration (Cmax) in plasma after zoledronic acid infusion.
Primary	Time to reach maximum concentration of Zoledronic acid	0-36 months	The time to reach the maximum concentration after administration (Tmax) in plasma after zoledronic acid infusion.
Primary	AUC of Zoledronic acid	0-36 months	The area under the concentration-time curve (AUC) in plasma after zoledronic acid infusion.
Primary	terminal half-life of Zoledronic acid	0-36 months	The terminal half-life (t1/2) of zoledronic acid after administration.
Primary	apparent clearance of Zoledronic acid	0-36 months	The apparent clearance (CL/F) of zoledronic acid after administration.
Primary	apparent volume of distribution of Zoledronic acid	0-36 months	The apparent volume of distribution of zoledronic acid after administration.
Primary	Concentration of bone turnover markers	0-36 months	Concentration-time profile of procollagen type 1 N-propeptide (P1NP), bone-specific alkaline phosphatase (ALP), osteocalcin (OCN), C-telopeptide (CTx), and tartrate-resistant acid phosphatase 5b (TRACP-5b) with unit of ng/mL.
Primary	Concentration of 25(OH)D and FGF23	0-36 months	Concentration determination of 25(OH)D and fibroblast growth factor 23 (FGF23) with unit of ng/mL
Primary	PTH concentration determination	0-36 months	Assessment of the profile of parathyroid hormone (PTH)
Primary	Serum sclerostin concentration determination	0-36 months	Concentration-time profile of sclerostin (SOST) after zoledronic acid infusion.
Primary	Pharmacodynamic of zoledronic acid	0-36 months	Assessment of lipid metabolism markers, such as low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol, and triglycerides.
Primary	Pharmacodynamic of zoledronic acid	0-36 months	Assessment of fibroblast growth factor 19 (FGF19).
Primary	Pharmacodynamic of zoledronic acid	0-36 months	Assessment of total bile acid.
Primary	Pharmacodynamic of zoledronic acid	0-36 months	Assessment of bone mineral density at the lumbar spine, neck of femur, and total hip.
Primary	Change of immune indicator	0-36 months	Changes in white blood cells(WBC)
Primary	Change of immune indicator	0-36 months	Changes in C reaction protein (CRP)
Primary	Change of immune indicator	0-36 months	Changes in interferon-γ (IFN-γ)
Primary	Change of immune indicator	0-36 months	Changes in interleukin-6 (IL-6)
Primary	Change of immune indicator	0-36 months	Changes in γδT cells activation

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04719650/registered

API reference For AI assistants

Registered outcomes21

Sources 3

Read this list from software.